Latest Regulatory Milestones News

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Macro Metals Limited is poised to resume trading on the ASX from July 18, 2025, following a key Supreme Court decision. The lifting of its trading suspension marks a significant regulatory milestone for the mining company.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Wia Gold Limited has significantly upgraded its Kokoseb Gold Project resource to 2.93 million ounces, advancing steadily toward a Definitive Feasibility Study targeted for late 2026. The company’s accelerated drilling and strong high-grade results underpin its ambition to become Namibia’s fourth commercial gold mine.

DP World Australia has secured Foreign Investment Review Board approval to acquire 100% of Silk Logistics, clearing a major regulatory hurdle for the deal.

High-Tech Metals has obtained crucial mining approvals and formed a joint venture to tap into historic gold stockpiles at its Mt Fisher Project, aiming for early cash flow and resource definition.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

EBR Systems has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for outpatient reimbursement of its WiSE® CRT System, marking a major step toward broader hospital adoption.

Star Minerals has made significant strides in developing its Tumblegum South Gold Project, signing a key MOU with MEGA Resources and completing a $1.6 million capital raise to support upcoming mining activities.

Imugene Limited reports promising Phase 1b trial results for azer-cel, an off-the-shelf CAR T therapy, showing a 75% overall response rate in relapsed diffuse large B-cell lymphoma patients. The company plans to engage the FDA later this year to discuss pivotal trial design.

VBX Limited has successfully listed on the ASX and revealed strong preliminary feasibility results for its Wuudagu Bauxite Project, positioning itself to capitalize on rising bauxite demand and supply uncertainties.